• IONIC’s sophisticated, premium vape pen line has earned a reputation as the top vape brand in Washington state
• The company’s acquisitions include a 140-acre farm in eastern Washington state that’s capable of producing 100,000 pounds of cannabis, as well as a licensed cannabis volatile extraction and manufacturing facility in California
• IONIC’s proprietary formulations of refined cannabis oils and distillates are used to create the popular Zoots Premium Cannabis Infused Edibles line

IONIC Brands Corp. (CSE: IONC) (OTC: ZRRRF) is a national cannabis holding company that’s building a multistate portfolio of award-winning premium and luxury brands in the cannabis space. Established in 2015, IONIC Brands is an industry leader with a proven ability to expand and operate multiple cannabis concentrate consumer brands in markets across the western United States.

The cornerstone brand of the company’s portfolio, IONIC, is recognized as the top vaporizer brand in Washington state and is currently available at dispensaries in Washington, Oregon, Nevada and California. The company recently signed a definitive agreement to acquire Natural Extractions Inc., also known as Zoots Premium Cannabis Infused Edibles, which is based in Washington state (http://ibn.fm/cI4wN). Zoots has developed consumer-proven formulas that will be preserved by IONIC Brands.

IONIC will be the first to launch Lucid Green Inc.’s revolutionary technology platform as an enrichment to the company’s Ionic Certified Clean Program, which guarantees that its cannabis products meet or exceed state mandates on pesticide testing. Lucid Green is designed to provide vital safety information to consumers with a simple smartphone scan of the QR code on a cannabis product, as detailed in a news release. Lucid Green provides access to a library of product specific insights instantaneously – including test results, dosage guidance, effects and more, while also providing IONIC loyalty rewards.

Distribution is a critical part of the cannabis supply chain in California, which is projected to grow from $3.7 billion in 2018 sales to $7.7 billion by 2021, according to Arcview Market Research (http://ibn.fm/Sl1wJ). To that end, Ionic recently signed an exclusive distribution agreement with Continuum, a California division of Origin House that delivers to more than 500 dispensaries in California. Origin House has the largest U.S. footprint of branded and distribution assets in North America, according to a news release (http://ibn.fm/R2ytP).

“IONIC Brands sought out the top distributor in California and given Origin House’s footprint, Ionic anticipates increased brand awareness, heightened demand for its products, and aggressive sales growth,” IONIC Chairman and CEO John Gorst stated in the release. “Our exclusive distribution agreement with Origin House distributor Continuum aligns with our strategy to build a multi-state, consumer-focused cannabis concentrate national brand portfolio focusing on the premium and luxury segments.”

IONIC Brands has also entered into a letter of intent to acquire the licensed cannabis volatile extraction and manufacturing assets of Kavry Management LLC, located in Adelanto, California. The licensed facility, near Los Angeles, fits the company’s strategic plan of vertical integration, Gorst stated in a news release (http://ibn.fm/JEvZQ).

“Securing this facility is a great foundation for IONIC Brands in California to advance our current premium luxury cannabinoid products,” Gorst continued. “We also see substantial development potential of new revenue streams through manufacturing in California.”

The company’s aim is to be the leader of the highest-value segments of the cannabis market by following its success on the West Coast with nationwide expansion. IONIC Brands is led by a team of successful entrepreneurs who are aggressively expanding the company by building a multistate, consumer-focused cannabis concentrate brand portfolio focusing on the premium and luxury segments of the cannabis industry.

For more information, visit the company’s website at www.IONIC.social

NOTE TO INVESTORS: The latest news and updates relating to ZRRRF are available in the company’s newsroom at http://ibn.fm/ZRRRF

• A presentation by INMB co-founder and CFO David Moss is slated for June 5 at 10:20 a.m., with one-on-one meetings also available
• The company’s active drug candidates are INKmune and INB03, which may be used to treat cancer, and XPro1595, which targets neuroinflammation as a cause of Alzheimer’s disease
• INMB received a $1 million grant from the Alzheimer’s Association to fund XPro1595 research and upcoming clinical trials in patients with Alzheimer’s disease

INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness patients’ innate immune systems to fight diseases, will share results of recent clinical advancements at the upcoming Ninth Annual LD Micro Invitational scheduled to take place at the Luxe Sunset Boulevard Hotel, June 4-5 in Bel-Air, California. Co-founder and CFO David Moss will lead INmune Bio’s presentation, which is set for June 5 at 10:20 a.m. PT, and participate in one-on-one meetings at the event, according to a news release (http://ibn.fm/sfg3n).

INmune Bio is pursuing several novel drug candidates that utilize a precision therapy approach to treat unsolved problems in medicine. Among the company’s active drug candidates are INKmune and INB03, which may be used to treat cancer, and XPro1595, which targets neuroinflammation as a cause of Alzheimer’s disease (http://ibn.fm/1LEh2). Inflammation, especially chronic inflammation, is being recognized as an important part of the pathology of many diseases, including cancer and Alzheimer’s disease/dementia, which currently affect an estimated 5.8 million Americans, according to the Alzheimer’s Association (http://ibn.fm/HFqZF).

INmune Bio has been recognized by the Alzheimer’s Association with a ‘Part the Cloud’ award that included a $1 million grant to further research into XPro1595 and the potential hope that it may bring to millions of patients with Alzheimer’s disease. INmune Bio expects to initiate an XPro1595 phase I clinical trial in patients with Alzheimer’s disease during the summer of 2019.

INmune Bio is also advancing several clinical trials featuring INB03 and INKmune – both of which are focused on “taking the brakes off” of the body’s innate immune system, making it a powerful weapon in the fight against cancer (http://ibn.fm/f5nhT). INB03 is a checkpoint inhibitor that targets cells resistant to immunotherapy to instead become therapeutically effective; INKmune primes a patient’s own natural killer cells to move from a resting state to an active state to attack and eliminate residual disease (lingering cancer cells) after cancer therapy.

INmune Bio recently posted its Q1 2019 financial results in a shareholder update, which highlighted the achievement of becoming the first biotechnology company to close an initial public offering (IPO) in 2019 and commence trading on the Nasdaq Capital Market (http://ibn.fm/RbQor).

INmune Bio also announced a common stock purchase agreement with Lincoln Park Capital Fund LLC, a Chicago-based institutional investor, for up to $20 million (subject to the terms of the agreements with Lincoln Park), which includes an initial investment of $300,000 (http://ibn.fm/GVLri). The investment is in addition to an earlier investment made by Lincoln Park during INmune Bio’s first round of funding in 2017, when the company was private.

“This financing agreement provides flexibility to opportunistically access capital at our option under favorable terms to advance our innate immune therapies in cancer and Alzheimer’s disease,” Moss said in a news release, noting that the funds will specifically help advance the company’s drug development pipeline into phase II clinical trials.

To schedule a one-on-one meeting with INmune Bio and Moss anytime during the LD Micro Invitational, contact KCSA Strategic Communications at INmune@kcsa.com

For more information, visit the company’s website at www.INmuneBio.com

NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB

• The company recently announced the upcoming acquisition in an all-stock transaction worth approximately C$48 million
• The alignment of values stemming from this transaction emphasizes Supreme’s dedication to providing premium products, education, support and customer care on a global level
• The acquisition takes Supreme one step closer to becoming a leading global provider of cannabis for personal wellbeing

The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1), Canada’s only coast-to-coast premium cannabis producer, recently announced its entry into a definitive arrangement agreement to acquire Blissco Cannabis Corp. in an all-stock transaction worth approximately C$48 million (http://ibn.fm/I5AWs). Blissco has built a distinct premium wellness brand that is expected to complement Supreme Cannabis’ growing portfolio.

Supreme Cannabis is one of the world’s fastest-growing premium plant-driven lifestyle companies. Blissco is set to join the company’s growing portfolio, which already includes 7ACRES, Cambium Plant Sciences, Medigrow Lesotho and Khalifa Kush Enterprises Canada.

Based in British Columbia, Blissco is a multi-licensed processor, cultivator and distributor of premium cannabis. The company is dedicated to providing premium products, education, support and customer care on a global level. From its beginnings, Blissco has valued environmental stewardship, health, wellness and personal well-being.

“Supreme Cannabis is the best-positioned company in the cannabis space to help Blissco achieve its ambition of delivering innovative, quality-assured, full-spectrum cannabis products to the world,” CEO Damian Kettlewell, who founded Blissco in 2013, stated in a news release. “By merging with Supreme Cannabis, Blissco shareholders will benefit from the combined expertise of both companies in growing premium cannabis brands, producing and procuring high-quality inputs, commercializing new products and ensuring regulatory compliance. Blissco shareholders will also benefit from Supreme Cannabis’ enhanced trading liquidity on the TSX and greater access to capital that will allow us to focus and accelerate Blissco’s premium wellness business.”

Per the update, Kettlewell will continue to lead Blissco, remain employed at Supreme Cannabis and retain 75 percent of his shares for a minimum of two years.

Blissco has worked hard to build a distinct brand, and this strategic partnership with Supreme Cannabis is expected to allow the company to focus on the production and commercialization of its premium wellness products. Together, Supreme Cannabis and Blissco will move toward the combined vision of improving global well-being with cannabis.

The arrangement will require approval by Blissco shareholders, and closing is subject to the approval of the Supreme Court of British Columbia, conditional approval from the TSX for listing the Supreme Cannabis Shares to be issued in connection with the Arrangement, receipt of required regulatory approvals and other customary conditions of closing.

For more information, visit the company’s website at www.Supreme.ca

NOTE TO INVESTORS: The latest news and updates relating to SPRWF are available in the company’s newsroom at http://ibn.fm/SPRWF

• Petroteq Energy has built a commercial facility in Utah’s deserts for proprietary technology that it believes will revolutionize the fuel industry with cost- and time-saving processes
• Petroteq’s flagship technology promises to make the most of domestic fuel sources at a time when foreign sources of heavy oils are facing trade uncertainties
• Petroteq recently completed a new funding round and is in the process of acquiring the operating rights and interests for additional oil resources on government land

During an era when geopolitical influences, automotive advances and market fluctuations have kept petroleum revenues well below historic record levels, pioneering technology developer Petroteq Energy Inc. (TSX.V: PQE) (OTC: PQEFF) is helping to revolutionize the oil and gas industry through the development of a cost-saving, environmentally friendly production platform.

Petroteq Energy’s flagship closed-loop surface oil extraction technology continues to attract industry attention in the surface oil sands resources of eastern Utah, where the company has been engaged in realizing its commercial facility by turning a bituminous surface minable tar sands resource into the commercial output of heavy oil while leaving behind a clean footprint.

On May 22, Petroteq announced the close of its most recent round of financing — a private placement for aggregate gross proceeds of $985,950, as well as two share-for-debt transactions (http://ibn.fm/IxDfp). The company has been in the process of ramping up continuous production at its Asphalt Ridge lease in Utah since late last year, selling oil to regional markets and expanding its facilities to help it reach its goal of delivering 5,000 to 8,000 barrels per day (bpd) of oil by 2022 as evidence of the technology’s effectiveness.

U.S. Department of Energy estimates put Utah’s undeveloped (but recoverable) oil resources at over 30 billion barrels (http://ibn.fm/YpPri). Engineers estimate that there are 139.5 million standard tank barrels (“STB”) of bitumen in place on Petroteq’s site, and the company recently announced the proposed acquisition of the operating rights and interests for oil sands under federal oil and gas leases in Utah encompassing some 8,480 gross acres in two areas that have been designated as “Special Tar Sands Areas” by the U.S. Bureau of Land Management (http://ibn.fm/vB9iD).

The “Evaluation of Contingent Resources” prepared by Chapman Petroleum Engineering Ltd., dated December 31, 2018, estimates that one of the leases, P.R. Spring, when combined with the prior acquisition of rights and interests under the lease, contains gross contingent resources of approximately 90 million barrels of mineable bitumen in place, with a net “arithmetic average after risk” estimate of 40.77 million barrels of mineable bitumen in place.

The company estimates that the resource amounts to an “after risk” cash flow value of $293.4 million on a 10 percent per year discounted basis and a cash flow value of $166.6 million on a 15 percent per year discounted basis.

The resource rights in the other area, the Tar Sands Triangle leases, are estimated at a gross contingent of 41.3 million barrels of bitumen in place, with a net “arithmetic average after risk” estimate of 20.7 million barrels of bitumen in place. No economic evaluation of those resources has been conducted.

Just as fracking revolutionized oil industry production by creating a feasible means of extracting fuels from domestic sources and reducing North America’s dependence on foreign sources, Petroteq expects its proprietary technology to innovate by using its recyclable solvent extraction process to exalt domestic sources of heavy fuels at a time of supply uncertainty from foreign producers, and to do it in a way that leaves the desert sands “cleaner” than they were initially.

The environmentally friendly process is suitable for all surface minable oil sands hydrocarbon deposits, and it may also be applied for remedial projects, according to the company.

“There’s no emissions, nothing to the air and nothing to the soil,” Petroteq President R. Gerald Bailey said in an Uptick Newswire interview last year (http://ibn.fm/f8NtI). “So, you could put plants on it and grow it after we get finished. So, there’s no environmental issues in this stuff and it’s very amenable to easy expansion.”

For more information, visit the company’s website at www.Petroteq.energy

NOTE TO INVESTORS: The latest news and updates relating to PQEFF are available in the company’s newsroom at http://ibn.fm/PQEFF

• The global precision medicine market is expected to reach revenues of over $216.75 billion by 2028, propelled by a growing interest in personalized approaches to disease treatments and the application of new technologies
• Precision Therapeutics and its three wholly owned subdivisions are advancing the company’s goals of applying artificial intelligence to precision medicine and drug research to improve patient care
• The company’s Helomics subdivision analyzes disease data, particularly in targeting cancer therapies, and develops applicable technologies; the TumorGenesis division develops tumor-fighting tactics, and the Skyline Medical division markets a device that facilitates biological fluid collection in the medical arena
• Helomics was recently selected as the lab of choice for a grant-funded effort to develop test kits for screening prescription drug contaminants

Personalized medicine technology developer Precision Therapeutics Inc. (NASDAQ: AIPT) has added a new biomedical research partnership to its portfolio, furthering its mission to apply artificial intelligence to precision medicine and drug discovery in an effort to improve the quality of patient care.

The innovative use of applied science in building artificial intelligence applications for medical advancement led Precision Therapeutics’ Helomics division to be selected as the preferred laboratory for the recently funded National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) grant to develop test kits for screening certain prescription drug contaminants.

The Accukit product will be used to test for microbial and viral contamination of biopharmaceuticals, with the goal of improving biosafety testing for biopharmaceutical products, according to the company’s statement about the agreement (http://ibn.fm/k1clX). AccuGenomics Inc., Celgene, Merck and North Carolina State University are also partnering in the enterprise.

Helomics will work on a highly sensitive Next Generation Sequencing-based platform to streamline screening biopharmaceuticals for the contaminants. The Accukit is expected to be able to detect 22 known but unintended viruses and bacteria at sensitivity levels required to pass strict quality control standards.

“The opportunity to contribute to innovative approaches to drug development is an important part of our business,” Helomics President Gerald Vardzel stated in a news release. “Our state of the art and highly recognized CLIA-certified lab in Pittsburgh contributes to our remaining at the cutting edge of innovation with leading edge partners that utilize our boutique contract research services.”

Helomics is one of three wholly owned Precision Therapeutics subsidiaries, the others being TumorGenesis and Skyline Medical. TumorGenesis is developing a new rapid approach to growing tumors in the laboratory to trick cancer cells into thinking they are still growing inside a patient, with the ultimate goal being to obtain information about the cells that can then be used to develop patient-specific treatment options. Skyline Medical markets the company’s patented and FDA-cleared STREAMWAY System for the automated collection, measurement and disposal of waste fluids within medical facilities, such as blood and surgical irrigation fluid.

Working together, Precision Therapeutics’ divisions advance its efforts to positively improve the effectiveness of cancer therapy using the power of AI and the company’s rich database of disease particulars gathered from the study of patient tumors to help patients and drive the development of new pharmaceutical therapies.

Precision medicine is a multibillion-dollar market that is gaining stature among populations of all ages, not only because of the therapies’ approach to individualized attention but also because of the growing use of technological advances for personal health care devices that include smart technologies. Precision medicine got a further push when the U.S. government’s Precision Medicine Initiative was introduced in 2015 (http://ibn.fm/QE0M6). Market analysts at BIS Research predict that, between 2018 and 2028, the global precision medicine market could grow from $78.85 billion to over $216.75 billion at a CAGR of 10.64 percent (http://ibn.fm/20FrL).

For more information, visit the company’s website at www.PrecisionTherapeutics.com

• The CFO of CIIX’s CBD Biotechnology Co. Ltd. is scheduled to speak at the microcap conference
• The company official is expected to share exciting new developments related to its hemp product line with current and prospective investors
• The company anticipates exciting opportunities for business growth in the coming months

ChineseInvestors.com Inc. (OTCQB: CIIX) will be an official presenter at the 9th Annual LD Micro Invitational to be held June 4-5 at the Luxe Sunset Boulevard Hotel in Bel-Air, California. Alex Hamilton, chief financial officer of CIIX’s wholly owned foreign enterprise, CBD Biotechnology Co. Ltd., will present a corporate overview at 2:20 p.m. PT on the opening day of the conference.

Hamilton will discuss recent business highlights with regard to the Chinese industrial hemp/CBD business. He will also be available for one-on-one meetings with investors during the conference.

“This conference is a great venue for emerging and rapid-growth companies,” Hamilton said in a news release (http://ibn.fm/LhGa0). “We are very much looking forward to sharing our exciting new developments of our hemp product line with current and prospective investors. We believe there will be some exciting opportunities for our business and growth expansions for our product lines in the coming months, which makes this an exciting time to be out sharing our corporate vision.”

The LD Micro Invitational conference began in 2006 with the purpose of being an independent resource in the microcap space. The June Invitational is scheduled to have 250 corporate participants and is expected to attract more than 1,000 attendees.

CIIX is a diverse company that offers its audience of Chinese-speaking investors real-time market commentary, analysis and education-related services in Chinese character language sets.

For more information, visit the company’s website at www.ChineseInvestors.com

NOTE TO INVESTORS: The latest news and updates relating to CIIX are available in the company’s newsroom at http://ibn.fm/CIIX

• SGSI is a leading provider of telecommunications engineering and infrastructure services and solutions
• The company is ready to meet the growing demand for 5G infrastructure
• SGSI recently announced multimillion-dollar revenue with positive income

Spectrum Global Solutions Inc. (OTCQB: SGSI) is a foremost provider of comprehensive outsourced services and solutions for the deployment and maintenance of next-generation and legacy wireless and wireline telecommunication networks and infrastructure. The company has successfully executed on projects across the United States and globally. Based in Longwood, Florida, Spectrum is professionally registered in 49 states, three U.S. territories (Puerto Rico, the Unites States Virgin Islands and Guam) and six Canadian provinces in support of its clients (http://ibn.fm/UJWDC).

The company provides services directly to carriers, aggregators, utilities, enterprise operations, project management organizations (PMOs) and original equipment manufacturer (OEM) clientele via diverse subsidiaries. These subsidiaries include AW Solutions Inc. and AW Solutions Puerto Rico LLC; ADEX Corporation and ADEX Puerto Rico LLC; Tropical Communications Inc.; and TNS Inc.

AW Solutions provides telecommunications and engineering services, along with cost-effective, scalable and strong solutions for organizations’ technology deployments (http://ibn.fm/i6jt8). ADEX Corporation provides turnkey services and project staffing solutions solely to the telecommunications industry. ADEX provides infrastructure services globally through domestic and international locations (http://ibn.fm/b7r9P).

Subsidiary Tropical Communications is a state-licensed electrical and underground utility contractor headquartered in Miami, Florida. It provides all kinds of communications and infrastructure facility structured wiring services and solutions (http://ibn.fm/l6oQ4). The TNS Inc. subsidiary specializes in the design, installation and maintenance of structured cabling systems using Tier 1 products (Mohawk, Hubbell, Berk-Tek, Ortronics and more). TNS’s Tier 1 testing equipment (Fluke DSX 1800) is used to test and certify every one of its installations (http://ibn.fm/jnx7T).

Spectrum Global Solutions’ services range in scope from a single activity to multiyear, multi-region large-scale turnkey development contracts. The company uses licensed professional engineers, project managers, technicians and general contractors. Through these experts, Spectrum has completed more than 150,000 project activities on wireless, DAS (Distributed Antenna System), wireline and fiber networks throughout the United States.

Spectrum is one of the few engineering and installation firms able to provide all services and bundle products for telcos. The company is focusing on its 5G networks rollout this year and is well-positioned to meet the increasing demand for 5G. The expectation is that the 5G rollout will create three million U.S. jobs and drive more than $500 billion in U.S. GDP growth (http://ibn.fm/0Q0Wx). Spectrum Global Solutions is among the few elite full-service engineering, construction, installation, maintenance and professional services organizations for these next-generation telecommunications networks.

Recently, Spectrum announced that it received new contract awards worth over $3.7 million to support carrier-network upgrades (http://ibn.fm/ZclhV). The company also recently reported financial results for the fiscal period ended March 31, 2019, with revenue of $11,335,732 for Q1 2019 versus $4,327,764 from Q1 2018 (http://ibn.fm/hKLFn).

“Revenue was just over $11.3 million, which reflects consistent growth in our AW Solutions, ADEX and TNS subsidiaries,” Spectrum CEO and President Roger Ponder stated in a news release. “We also reported positive income from operations for the period. This is Spectrum’s first quarter with positive income from operations, which demonstrates continued improvements in the business.”

Spectrum Global Solutions offers a compelling investment opportunity with its ability to provide a full slate of telecommunications and enterprise services. The company has embedded customer relationships that foster repeat customers at minimal customer acquisition costs, and it continues to be a proven operator in the high-growth telecom market.

For more information, visit the company’s website at www.SpectrumGlobalSolutions.com

NOTE TO INVESTORS: The latest news and updates relating to SGSI are available in the company’s newsroom at http://ibn.fm/SGSI

• The company is now able to fulfill inquiries about white labeling its full-spectrum cannabinoids line
• ETST has added markets for CBD products through two distribution agreements
• The company continues to eye product placement in large chain and health food stores, dispensaries, chiropractor offices, athletic clubs and clinics

Earth Science Tech Inc. (OTCQB: ETST), a biotech company focused on the nutraceutical and pharmaceutical fields, is seeking to gain more market share through its white-label initiative that offers marketers the ability to rebrand its full-spectrum cannabinoids line (http://ibn.fm/frikT).

“I’m excited to share that our sales have consistently increased over 100% every month,” ETST Chairman Nickolas S. Tabraue stated in a news release. “We have also received countless white-labeling inquiries, and thanks to our reliable source and manufacturer, we are now able to fulfill these inquiries and capture even more market share.”

White labeling enables a company to benefit from the branding and distribution channels of other brands (http://ibn.fm/wfJTD) and is a strategy designed to create more loyalty and insular protection for ETST in the competitive cannabis market. ETST has collaborated with its manufacturing partner to launch the white labeling initiative (http://ibn.fm/oJzGf).

This program is expected to help ETST gain market share at a time when the company is also broadening its target markets to include larger chain and health food stores, pharmacies, dispensaries, chiropractor offices, athletic clubs and clinics. ETST has signed agreements with Desert Sun Distribution and Cannabiz to distribute to health care practitioners and pharmacies.

Based in Doral, Florida, ETST offers cannabinoids in the form of softgels, tablets, liquids and other options classified as food-based and permissible in all 50 states in the United States and some 40 countries globally.

For more information, visit the company’s website at www.EarthScienceTech.com

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at http://ibn.fm/ETST

• MRMD improved its adjusted EBITDA in Q1 2019 by 76 percent
• The company’s multipronged strategy for growth includes continued consolidation of cannabis operations and the launch of a subsidiary
• MariMed CEO identified the company as a “significant early mover” in the burgeoning CBD health and wellness market

MariMed Inc. (OTCQB: MRMD) recorded a 69 percent jump in revenues to $3,515,815 for the three months ended March 31, 2019, as compared to $2,082,950 for the comparable period of the prior year. The company’s gross profit for the quarter rose 90 percent, to $2,261,025, from $1,194,081 for the same period in 2018. MRMD is actively pursuing additional growth as it moves to expand brand licensing and open more cannabis facilities in several states (http://ibn.fm/yrLJg).

MRMD’s adjusted EBITDA increased 76 percent to $585,000 in Q1 2019, up from $332,000 in the comparable period of the prior year. Reported net loss for the same quarter was $23,211, marking a 99 percent improvement from the $1,895,142 loss reported in the same period of 2018.

MariMed has adopted a multipronged strategy for growth in 2019. That strategy includes continuing consolidation of operations, which is expected to be completed over the next several months, and the launch of MariMed Hemp Inc., a wholly owned subsidiary in the hemp-based CBD market for health and wellness products. Marimed is developing new CBD brands and products that will be distributed to retailers and reps of health and medical businesses.

“We continue to see dynamic growth in our cannabis operations, even as we have become a significant early mover in the burgeoning CBD health and wellness market,” MRMD CEO Bob Fireman stated in a news release (http://ibn.fm/EvN0I). “We are encouraged by our continued strong operating performance, and look forward to realizing the benefits of investments and initiatives undertaken over the last two quarters, which includes the ongoing consolidation of cannabis operations, the opening of additional cannabis facilities in several states, expanding the licensing of our brands and products into additional licensed states, and our multipronged entry into the CBD market.”

MRMD offers a full range of cannabis products, operates dispensaries in six states and is focused on the development of MariMed Hemp. MariMed Hemp owns a significant share of Kentucky-based GenCanna Global Inc., an industrial hemp genetic innovator. MRMD recently converted debt investment (debentures) in GenCanna Global into a significant equity position in that company, which is a leader in vertically integrated hemp cultivation and a producer of Good Manufacturing Practices-compliant CBD products.

For more information, visit the company’s website at www.MariMedAdvisors.com

• Endonovo’s flagship product, SofPulse, is an easy-to-place, non-invasive device delivering pulsed electromagnetic frequencies to enhance post-surgical recovery
• The company’s agreement with Veterans Healthcare Supply Solutions Inc. includes distribution of SofPulse to Veterans Administration facilities and Department of Defense health care facilities
• Treatment with SofPulse allows patients to better manage post-operative pain without the adverse side effects of narcotics and anti-inflammatory medications
• Endonovo holds patents and trademarks for several proprietary technologies and devices

Endonovo Therapeutics Inc. (OTCQB: ENDV) is a commercial stage developer of non-invasive medical devices designed to deliver proprietary, patent protected Electroceutical Therapy for the treatment of inflammatory conditions, cardiovascular diseases and central nervous system disorders. As an innovative biotechnology company, Endonovo is harnessing bioelectricity to restore key electrochemical processes that initiate the anti-inflammatory and growth factor cascades necessary for healing to occur.

The long-term agreement recently signed with Veterans Healthcare Supply Solutions Inc. (“VHSS”) to directly distribute SofPulse devices to Veterans Administration facilities and Department of Defense health care facilities extends beyond traditional distribution methods, Endonovo CEO Alan Collier said in a news release (http://ibn.fm/MHvji).

“The team at VHSS have streamlined and improved the sales, marketing and distribution of medical devices to VA and DoD facilities. VHSS is a true leader in the space and we are thrilled to have the capacity to support their mission,” Collier stated in a news release. “This agreement, which includes direct delivery to all medical facilities, extends beyond traditional distribution and includes access to their 900 Federal Contract Officers as well as their distribution center with a state-of-the-art ERP and WMS Systems.”

Endonovo’s flagship product, SofPulse, is an easy-to-place, non-invasive device delivering pulsed electromagnetic frequencies to enhance post-surgical recovery, and it can be used as a standalone therapy or integrated into any treatment protocol. SofPulse uses targeted microcurrents to transmit gentle pulses to the tissue to help reduce swelling and speed up the natural recovery process.

“VHSS is excited to partner with Endonovo, as our primary goal is providing leading edge products and services to eligible federal government health care constituents,” added Gary Skura, VHSS president and retired Navy pilot with over 30 years of health care distribution experience. “Our new partnership with Endonovo will certainly allow us to further continue our core objectives.”

Endonovo’s Electroceutical Therapy is cleared by the U.S. Federal Drug Administration (FDA) for the palliative treatment of post-surgical pain and edema (swelling) and is CE-marked in the European Economic Area (EEA) for the promotion of wound healing and the palliative treatment of post-surgical pain and edema. The Centers for Medicare and Medicaid Services (CMS) also has national coverage determination for the reimbursement of Electroceutical Therapy for the treatment of chronic wounds.

For more information, visit the company’s website at www.Endonovo.com

NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV